C1 inhibitor ELISA Kit, Human General Information
C1 inhibitor ELISA Kit, Human
Solid Phase Sandwich ELISA (quantitative)
Recognizes both recombinant and natural Human C1 inhibitor
The recovery of Human SerpinG1 spiked to different levels throughout the range of the assay in related matrices was evaluated.
||Average % Recovery
||Recovery of detected
1. 96 well microplate coated with Capture Antibody
2. Detection Antibody conjugated to HRP
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
This C1 inhibitor ELISA Kit, Human is an enzyme-linked immunosorbent assay for the quantitative measurement of Human C1 inhibitor protein in Serum . It contains recombinant Human C1 inhibitor, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use.
This ELISA Kit is shipped at ambient temperature.
Unopened Kit: Store at 2 - 8℃
Opened/Reconstituted Reagents: Please refer to CoA
C1 inhibitor ELISA Kit, Human Images
This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.
This assay recognizes both recombinant and natural Human SerpinG1. The factors listed above were prepared at 60 ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed.
C1 inhibitor ELISA Kit, Human Alternative Names
C1IN ELISA Kit, Human;C1INH ELISA Kit, Human;C1NH ELISA Kit, Human;HAE1 ELISA Kit, Human;HAE2 ELISA Kit, Human
C1 inhibitor Background Information
Plasma protease C1 inhibitor, also known as C1-inhibiting factor, C1-INH, C1 esterase inhibitor, SERPING1 and C1IN, is a serine proteinase inhibitor (serpin) that regulates activation of both the complement and contact systems. By its C-terminal part (serpin domain), characterized by three beta-sheets and an exposed mobile reactive loop, C1-INH binds, and blocks the activity of its target proteases. The N-terminal end (nonserpin domain) confers to C1-INH the capacity to bind lipopolysaccharides and E-selectin. Owing to this moiety, C1-INH intervenes in regulation of the inflammatory reaction. The heterozygous deficiency of C1-INH results in hereditary angioedema (HAE). Owing to its ability to modulate the contact and complement systems and the convincing safety profile, plasma-derived C1 inhibitor is an attractive therapeutic protein to treat inflammatory diseases other than HAE. Deficiency of C1 inhibitor results in hereditary angioedema, which is characterized by recurrent episodes of localized angioedema of the skin, gastrointestinal mucosa or upper respiratory mucosa. C1 inhibitor may prove useful in a variety of other diseases including septic shock, reperfusion injury, hyperacute transplant rejection, traumatic and hemorrhagic shock, and the increased vascular permeability associated with thermal injury, interleukin-2 therapy and cardiopulmonary bypass.
serpin peptidase inhibitor, clade G (C1 inhibitor), member 1
Davis AE 3rd. et al. (2004) Biological effects of C1 inhibitor. Drug News Perspect. 17(7): 439-46.Cicardi M, et al. (2005) C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol. 27(3): 286-98.Wouters D, et al. (2008) C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther. 8(8): 1225-40.Cugno M, et al. (2009) C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 15(2): 69-78.